People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Other Health Care, Pharmaceuticals, Biotechnology, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avedro Inc | — | Other Health Care | Series C | $158.4M | $571.6M | 2009 |
| Agios Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $86.8M | $2.7B | 2010 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2011 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2009 |
| Black Hills Fiberglass, LLC | — | Manufacturing | Seed | $1.2M | $14.7M | 2012 |
| eWELLNESS HEALTHCARE Corp | — | Other Health Care | Pre-Seed | $698K | $3.7M | 2014 |
Doug Cole at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Doug Cole on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Robert Langer | 1 | 36 |
| Garheng Kong | 1 | 16 |
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Jonathan Silverstein | 1 | 10 |
| Alan Crane | 1 | 9 |
| Robert Nelson | 1 | 7 |
| Reza Zadno | 1 | 7 |
| Harry Wilcox | 1 | 6 |
| Philip J. Ferneau | 1 | 6 |
| Sheila Gujrathi | 1 | 5 |
| Anthony J. Natale | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Gilbert H. Kliman | 1 | 5 |
| Joseph Mandato | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| Gilbert Kliman | 1 | 4 |
| PETER HUTT | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.